Susan C. Guba

3.0k citations

49 papers · 2.4k indexed · 1 hit paper · h-index 22

Oncology top 2%
- Lung Cancer Research Studies 13
- Colorectal Cancer Treatments and Studies 8
- Pancreatic and Hepatic Oncology Research 8
- Cancer Treatment and Pharmacology 5
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 16
- Lung Cancer Diagnosis and Treatment 9
Cancer Research top 5%
- Cancer Genomics and Diagnostics 7
Genetics top 5%
Hematology top 5%
Molecular Biology
- TGF-β signaling in diseases 5

Co-authors: Louis M. Fink Ivelina Gueorguieva Vivian Fonseca Ann Cleverly Shawn T. Estrem Karim A. Benhadji Coleman K. Obasaju Mark A. Socinski
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Journal of Clinical Investigation (2 papers)Journal of Clinical Oncology (17 papers)Blood (3 papers)
Partner nations: United States United Kingdom Italy

In The Last Decade

Susan C. Guba

49 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Susan C. Guba

Since Specialization

Citations

This map shows the geographic impact of Susan C. Guba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan C. Guba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan C. Guba more than expected).

Fields of papers citing papers by Susan C. Guba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan C. Guba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan C. Guba. The network helps show where Susan C. Guba may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Susan C. Guba, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Susan C. Guba Line = papers co-authored together Susan C. Guba links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer BMC Cancer ·Ernest Nadal,Mansoor N. Saleh,Santiago Ponce Aix,María Ochoa-de-Olza,Sandip Pravin Patel,Scott Antonia,Yumin Zhao,Ivelina Gueorguieva,Michael Man,Shawn T. Estrem,Jiangang Liu,Emin Avşar,Wen Lin,Karim A. Benhadji,Leena Gandhi,Susan C. Guba,Inmaculada Alés Díaz	2023	36
2	Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer Clinical Cancer Research ·Christopher J. Sweeney,Ivor Percent,Sunil Babu,Jennifer L. Cultrera,Bryan A. Mehlhaff,Oscar B. Goodman,David Morris,Ian D. Schnadig,Costantine Albany,Neal D. Shore,Paul Sieber,Susan C. Guba,Yaoguang Zhang,Volker Wacheck,Gregory P. Donoho,Anna M. Szpurka,Sophie Callies,Boris K. Lin,Johanna C. Bendell	2022	31
3	Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer Journal for ImmunoTherapy of Cancer ·Davide Melisi,Do‐Youn Oh,Antoine Hollebecque,Emiliano Calvo,Anna M. Varghese,Erkut Borazanci,Teresa Macarulla,Valeria Merz,Camilla Zecchetto,Yumin Zhao,Ivelina Gueorguieva,Michael Man,Leena Gandhi,Shawn T. Estrem,Karim A. Benhadji,Mark C. Lanasa,Emin Avşar,Susan C. Guba,Rocio García‐Carbonero	2021	149
4	Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma Investigational New Drugs ·Antje Wick,Annick Desjardins,Cristina Suárez,Peter Forsyth,Ivelina Gueorguieva,Tiana L. Burkholder,Ann Cleverly,Shawn T. Estrem,Shuaicheng Wang,Michael Lahn,Susan C. Guba,David Capper,Jordi Rodón	2020	94
5	Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes Clinical Cancer Research ·Valeria Santini,David Valcárcel,Uwe Platzbecker,Rami S. Komrokji,Ann Cleverly,Michael Lahn,Jan Janßen,Yumin Zhao,Alan Y. Chiang,Aristoteles Giagounidis,Susan C. Guba,Ivelina Gueorguieva,Allicia C. Girvan,Mariana da Silva Ferreira,Tushar D. Bhagat,Kith Pradhan,Ulrich Steidl,Ashwin Sridharan,Britta Will,Amit Verma	2019	60
6	A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Journal of Clinical Oncology ·Davide Melisi,Antoine Hollebecque,Do‐Youn Oh,Emiliano Calvo,Anna M. Varghese,Erkut Borazanci,T. Macarulla Mercadé,Francesca Simionato,Joon Oh Park,Johanna C. Bendell,Sandrine Faivre,Yumin Zhao,Ivelina Gueorguieva,Michael Man,Shawn T. Estrem,Karim A. Benhadji,Mark C. Lanasa,Susan C. Guba,Rocio García‐Carbonero	2019	26
7	Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients Annals of Oncology ·Jyoti D. Patel,J. R. Pereira,J. Chen,J. Liu,Susan C. Guba,William J. John,Mauro Orlando,Giorgio V. Scagliotti,Philip Bonomi	2016	28
8	A phase 1b/2 dose escalation and cohort expansion study of the safety, tolerability and efficacy of a transforming growth factor-beta (TGF-&bgr;) receptor I kinase inhibitor (galunisertib) in combination with anti–PD-1 (nivolumab) in advanced refractory solid tumours Annals of Oncology ·Susan C. Guba,Saikat Mukhopadhyay,D. Desaiah,Valérie André	2016	1
9	Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer Journal of Thoracic Oncology ·David R. Spigel,Jyoti D. Patel,Craig H. Reynolds,Edward B. Garon,Robert C. Hermann,Ramaswamy Govindan,Mark R. Olsen,Katherine B. Winfree,Jian Chen,Jingyi Liu,Susan C. Guba,Mark A. Socinski,Philip Bonomi	2015	22
10	Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition Journal for ImmunoTherapy of Cancer ·David Schaer,Yanxia Li,Stephen Castaneda,Ivan Inigo,David Surguladze,Xiaohong Xu,Desiree Nugent,Mary Y. Murphy,Gerald E. Hall,Karim A. Benhadji,Susan C. Guba,Yiwen Li,Michael Kalos,Kyla Driscoll	2015	1
11	PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer Journal of Thoracic Oncology ·Ralph Zinner,Coleman K. Obasaju,David R. Spigel,Robert Weaver,J. Thaddeus Beck,David Waterhouse,Manuel Modiano,Borys Hrinczenko,Petros Nikolinakos,Jingyi Liu,Andrew Koustenis,Katherine B. Winfree,Symantha Melemed,Susan C. Guba,Waldo Ortuzar,D. Desaiah,Joseph Treat,Ramaswamy Govindan,Helen J. Ross	2014	120
12	Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin Lung Cancer ·Martin Reck,Nick Thatcher,Egbert F. Smit,Paul Lorigan,Ewa Szutowicz-Zielińska,Astra M. Liepa,Katherine B. Winfree,Patrick Peterson,Susan C. Guba,Mark A. Socinski	2012	24
13	Patient (Pt) and caregiver (Cg) perspectives in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·Corey J. Langer,Tracey L. Evans,Chandra P. Belani,Gary Middleton,C. Chouaïd,K Pearson,Daniel Ball,Elizabeth Nicole Bush,Susan C. Guba,Johan Vansteenkiste	2012	1
14	Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer Clinical Lung Cancer ·Jyoti D. Patel,Philip Bonomi,Mark A. Socinski,Ramaswamy Govindan,Shengyan Hong,Coleman K. Obasaju,Eduardo J. Pennella,Allicia C. Girvan,Susan C. Guba	2009	62
15	The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis Cancer Chemotherapy and Pharmacology ·Robert L. Fine,David R. Fogelman,Stephen M. Schreibman,Manisha Desai,William H. Sherman,J.B. Strauss,Susan C. Guba,Riolan Andrade,John A. Chabot	2007	71
16	Hyperhomocysteinemia and Thrombosis Seminars in Thrombosis and Hemostasis ·Susan C. Guba,Vivian Fonseca,Louis M. Fink	1999	56
17	The Authors’ Reply American Journal of Clinical Pathology ·Susan C. Guba,Louis M. Fink,Vivian Fonseca	1997	1
18	Hyperhomocysteinemia:An Emerging and Important Risk Factor for Thromboembolic and Cardiovascular Disease American Journal of Clinical Pathology ·Susan C. Guba,Louis M. Fink,Vivian Fonseca	1996	78
19	Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. Journal of Clinical Investigation ·Gargi Upadhyaya,Susan C. Guba,S A Sih,Andrew P. Feinberg,Moshe Talpaz,H. Kantarjian,AB Deisseroth,SG Emerson	1991	73
20	Regulation of interleukin 3 gene induction in normal human T cells. Journal of Clinical Investigation ·Susan C. Guba,Giulia Maria Stella,L A Turka,Carl H. June,Craig B. Thompson,SG Emerson	1989	39

About Susan C. Guba

Susan C. Guba is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine, having authored 49 papers that have together received 2.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (16 papers), Lung Cancer Research Studies (13 papers), Lung Cancer Diagnosis and Treatment (9 papers), Colorectal Cancer Treatments and Studies (8 papers), Pancreatic and Hepatic Oncology Research (8 papers), Cancer Genomics and Diagnostics (7 papers), TGF-β signaling in diseases (5 papers) and Cancer Treatment and Pharmacology (5 papers). The work is most often cited by research in Oncology (1.3k citations), Pulmonary and Respiratory Medicine (784 citations) and Cancer Research (350 citations). Susan C. Guba has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Louis M. Fink, Ivelina Gueorguieva, Vivian Fonseca, Ann Cleverly, Shawn T. Estrem, Karim A. Benhadji, Coleman K. Obasaju, Mark A. Socinski, Michael Lahn and Kyla Driscoll. Their work appears in journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact